[PDF] Top 20 Estabilización de suelos con bacterias Sporosarcina pasteurii

... with coronary heart disease are often accompanied by severe mood changes and poor mental ...the disease- associated knowledge in detail for the patients and their ...of coronary ... See full document

... the clinical efficacy of atorvastatin plus trimetazidine for treatment of patients with coronary heart disease, examining the effect mechanisms on myocardial and renal ... See full document

... and treatment of coronary heart ...recommended treatment on the basis of specified cut-off ...on coronary prevention [40], hyperlipidemia [41,42], hypertension [43], and diabetes ... See full document

... for coronary heart disease by evaluating patient self-care ability, quality of life, and drug therapy ...conventional clinical care. The experimental group received clinical care plus ... See full document

... occluded coronary arteries by intracoronary infusion of the fibrinolytic agent streptokinase 41 .... Coronary angioplasty and stenting 44 , together with newer, more potent platelet inhibitors (P2Y12 and ... See full document

... potential treatment effect for failing hearts by using a class of drugs such as trimetazidine and ranolazine, which can shift the lipid and glucose metabolic states in myocardial cells ... See full document

... cardiovascular disease, dementia, or major physical disability, the daily use of 100 mg of enteric-coated aspirin did not differ significantly from placebo in influ- encing the rates of disability-free survival at ... See full document

... for treatment of cor- onary heart disease, but the expenses are quite ...specific disease conditions of patients, increase the economic burden of patients and ...arrhythmia, heart ... See full document

... Given the low prevalence of LMS disease, the numbers in this prospective study are limited. In our study SPECT analysis did not use attenuation correction; however this was not routine practice when the study was ... See full document

... In clinical trials, tivantinib in association with erlotinib showed superiority over erlotinib plus ...metastatic disease compared with erlotinib plus ...classical clinical trial endpoint, it could ... See full document

... received treatment on study and were evaluable for ...refractory disease in 72% of cases, CR in 20% of cases, and PR in 8% of ...CNS disease, decreased fibrinogen (5%), or thrombosis ...of ... See full document

... The average concentration of blood choles- terol within a population is an important determinant of the risk of CHD in the popula- tion. In countries where the average cholesterol concentrations of the population are ... See full document

... Several mechanisms have been suggested to account for the observed protective effect of marital status on CVD especially in men. Social causation theory suggests that individuals benefit from spousal support.[43] For ... See full document

... Results: We retrieved 755 potentially relevant papers through searches of electronic and gray literature, of which only 13 met inclusion criteria after the screening and were included in this review. Of the studies that ... See full document

... kidney disease cannot be administered doses of allopurinol sufficient to lower uric ...kidney disease, in whom it is difficult achieve target uric acid levels using conventional uric acid-lowering ... See full document

... after coronary incidents carried out by the Mayo Clinic Institution proved that prop- erly conducted CR program in patients after myocardial infarction is able to re- duce all-cause mortality by 45% - 47% ...and ... See full document

... controlled, Phase III trial, 493 Asian patients were enrolled. Patients were randomly assigned (2:1) to intravenously receive 3 mg/kg of nivolumab or placebo every 2 weeks. OS was the primary end point in the ... See full document

... the efficacy of pregabalin in 747 patients, randomly assigned to receive 300, 450, and 600 mg/day of pregabalin or placebo (a total of 73 centers across Europe, Canada, Asia, and ... See full document

... from clinical trials have conclusively shown that statins lower the risk of morbidity and mortality associated with cardiovascular ...to coronary heart disease ... See full document

... of treatment was 95 days in everolimus and 57 days in placebo ...respectively. Treatment in both cohorts continued until progression, severe toxicity, death or ... See full document